Wet Age-Related Macular Degeneration
KSI-301 for wet AMD fails to meet primary endpoint in phase 2b/3 trial
In a phase 2b/3 clinical trial, KSI-301 failed to meet the primary endpoint of noninferior visual acuity gains compared with aflibercept in subjects with wet age-related macular degeneration, according to a Kodiak Sciences press release.
VIDEO: EYP-1901 shows consistent safety results at 8 months
In this Healio Video Perspective, Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, discusses EYP-1901 for the treatment of wet age-related macular degeneration.
High-dose aflibercept shows promise in wet AMD treatment
VIDEO: Two-year data show good visual, anatomic outcomes for Susvimo in wet AMD
In this Healio video exclusive, Charles C. Wykoff, MD, PhD, discusses 2-year results from the Archway study of Susvimo (ranibizumab injection, Genentech) to treat wet AMD, presented at Angiogenesis, Exudation, and Degeneration 2022.
FDA approves Vabysmo for treatment of wet AMD, DME
The FDA has approved Vabysmo for the treatment of wet age-related macular degeneration and diabetic macular edema, according to a press release from Genentech.
One-year trial results show efficacy, safety of longer-interval faricimab for wet AMD, DME
One-year results of four phase 3 trials of faricimab showed safety and efficacy comparable to aflibercept in the treatment of wet age-related macular degeneration and diabetic macular edema, with potentially longer treatment intervals.
Regenxbio initiates second pivotal trial of gene therapy for wet AMD
Regenxbio has initiated a second phase 3 pivotal trial investigating RGX-314 in patients with wet age-related macular degeneration, according to a press release.